At Bancorp Has Upped Its Morgan Stanley (MS) Stake; Progenics Pharmaceuticals Has 1.29 Sentiment

November 14, 2017 - By Neil V. Hobbs

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $372.43 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It currently has negative earnings. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.

At Bancorp increased Morgan Stanley (MS) stake by 184.45% reported in 2017Q2 SEC filing. At Bancorp acquired 10,654 shares as Morgan Stanley (MS)’s stock declined 9.43%. The At Bancorp holds 16,430 shares with $732,000 value, up from 5,776 last quarter. Morgan Stanley now has $87.48 billion valuation. The stock declined 0.51% or $0.25 reaching $48.39 on the news. About 4.50 million shares traded. Morgan Stanley (NYSE:MS) has risen 57.08% since November 14, 2016 and is uptrending. It has outperformed by 40.38% the S&P500.

At Bancorp decreased Celgene Corp (NASDAQ:CELG) stake by 4,366 shares to 5,558 valued at $722,000 in 2017Q2. It also reduced British Amern Tob Plc (NYSEMKT:BTI) stake by 10,349 shares and now owns 5,429 shares. Aegon N V (NYSE:AEG) was reduced too.

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.21, from 1.09 in 2017Q1. It dived, as 71 investors sold MS shares while 297 reduced holdings. 73 funds opened positions while 252 raised stakes. 1.55 billion shares or 0.70% less from 1.56 billion shares in 2017Q1 were reported. Nomura Asset Mgmt stated it has 178,477 shares. Moreover, Boys Arnold & Inc has 0.13% invested in Morgan Stanley (NYSE:MS) for 23,115 shares. Segantii Cap Mngmt, Hong Kong-based fund reported 200 shares. First Midwest Comml Bank Trust Division reported 64,616 shares. Pacific Glob Investment Management has 0.16% invested in Morgan Stanley (NYSE:MS) for 15,906 shares. Amer Century invested in 0% or 39,347 shares. Proshare Advsrs holds 0.15% of its portfolio in Morgan Stanley (NYSE:MS) for 327,023 shares. Mitsubishi Ufj Gru Inc invested in 100% or 432.02M shares. Hancock Holding reported 85,192 shares. Montag A & Assoc owns 68,754 shares for 0.34% of their portfolio. Hightower Advsr Limited Com reported 263,270 shares or 0.1% of all its holdings. Pictet Asset Ltd has invested 0.09% in Morgan Stanley (NYSE:MS). Pillar Pacific Capital Mngmt Limited invested in 126,683 shares. Greenleaf stated it has 0.01% of its portfolio in Morgan Stanley (NYSE:MS). Essex Financial Svcs owns 14,257 shares.

Among 29 analysts covering Morgan Stanley (NYSE:MS), 17 have Buy rating, 0 Sell and 12 Hold. Therefore 59% are positive. Morgan Stanley had 82 analyst reports since July 21, 2015 according to SRatingsIntel. As per Tuesday, April 19, the company rating was maintained by Wood. The stock of Morgan Stanley (NYSE:MS) has “Buy” rating given on Thursday, August 20 by Zacks. BMO Capital Markets maintained Morgan Stanley (NYSE:MS) rating on Thursday, July 20. BMO Capital Markets has “Outperform” rating and $61 target. Buckingham Research upgraded the stock to “Buy” rating in Tuesday, August 25 report. The firm earned “Buy” rating on Friday, October 6 by RBC Capital Markets. The stock has “Buy” rating by Buckingham Research on Wednesday, October 18. The firm has “Buy” rating given on Thursday, July 20 by Bank of America. The company was maintained on Wednesday, October 18 by Barclays Capital. HSBC upgraded the stock to “Buy” rating in Friday, September 15 report. The stock of Morgan Stanley (NYSE:MS) earned “Neutral” rating by Guggenheim on Thursday, July 30.

About 635,193 shares traded. Progenics Pharmaceuticals, Inc. (PGNX) has risen 48.41% since November 14, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 2 Wall Street analysts rating Progenics Pharm, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. PGNX was included in 2 notes of analysts from October 27, 2016. The rating was initiated by Aegis Capital on Thursday, October 27 with “Buy”. On Monday, February 6 the stock rating was upgraded by Needham to “Strong Buy”.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 8. They expect $-0.21 earnings per share, down 110.00% or $0.11 from last year’s $-0.1 per share. After $-0.22 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.55% EPS growth.

Phocas Financial Corp. holds 1.03% of its portfolio in Progenics Pharmaceuticals, Inc. for 1.47 million shares. Broadfin Capital Llc owns 1.00 million shares or 0.83% of their US portfolio. Moreover, Ardsley Advisory Partners has 0.62% invested in the company for 510,000 shares. The California-based Rice Hall James & Associates Llc has invested 0.4% in the stock. Park West Asset Management Llc, a California-based fund reported 907,351 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.